Brand Name

Dactinomycin

View Brand Information
FDA approval date: July 31, 2019
Classification: Actinomycin
Form: Injection

What is Dactinomycin?

Dactinomycin for injection is an actinomycin indicated for the treatment of: adult and pediatric patients with Wilms tumor, as part of a multi-phase, combination chemotherapy regimen.
Save this treatment for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms

Related Clinical Trials

PNOC031: Protocol for Embryonal Tumor With Multilayered Rosettes (ETMR)

Summary: This is an open-label, comprehensive, iterative investigation of evaluating the use of induction chemotherapy, high-dose chemotherapy, and focal radiation therapy in children with newly diagnosed Embryonal Tumor With Multilayered Rosettes (ETMR).

Metastatic Ewing's Trial Testing Schedule Enhancement to Improve Outcomes

Summary: This single arm study is designed to demonstrate the feasibility of a radically different approach for an exceptionally high-risk subset of MES with widely metastatic disease (WMES). We incorporate the use of evolutionary principles that apply to species and population dynamics as related to adaptation and extinction to populations of cancer cells that similarly adapt and that we are attempting to...

Risk Adapted Treatment of Unilateral Favorable Histology Wilms Tumors (FHWT)

Summary: This phase III trial studies using risk factors in determining treatment for children with favorable tissue (histology) Wilms tumors (FHWT). Wilms Tumor is the most common type of kidney cancer in children, and FHWT is the most common subtype. Previous large clinical trials have established treatment plans that are likely to cure most children with FHWT, however some children still have their canc...